Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors.

Autor:	Konnova A; Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.; Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium., De Winter FHR; Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium., Gupta A; Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.; Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium., Verbruggen L; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium., Hotterbeekx A; Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium., Berkell M; Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.; Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium., Teuwen LA; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Vanhoutte G; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Peeters B; Department of Laboratory Medicine, Antwerp University Hospital, Edegem, Belgium., Raats S; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium., der Massen IV; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium., De Keersmaecker S; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium., Debie Y; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Huizing M; Biobank, Antwerp University Hospital, Edegem, Belgium., Pannus P; Scientific Directorate Epidemiology and Public Health, Sciensano, Brussels, Belgium., Neven KY; Scientific Directorate Epidemiology and Public Health, Sciensano, Brussels, Belgium.; Centre for Environmental Sciences, Hasselt University, Hasselt, Belgium.; Federal Public Service (FPS) Health, Food Chain Safety and Environment, Brussels, Belgium., Ariën KK; Virology Unit, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.; Department of Biomedical Sciences, University of Antwerp, Edegem, Belgium., Martens GA; Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium., Bulcke MVD; Scientific Directorate Epidemiology and Public Health, Sciensano, Brussels, Belgium., Roelant E; Clinical Trial Center (CTC), Clinical Research Centre (CRC) Antwerp, Antwerp University Hospital, University of Antwerp, Edegem, Belgium.; StatUa, Center for Statistics, University of Antwerp, Antwerp, Belgium., Desombere I; Service Immune response, Scientific Directorate Infectious Diseases in Humans, Sciensano, Brussels, Belgium., Anguille S; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Berneman Z; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Goossens ME; Scientific Directorate Infectious Diseases in Humans, Sciensano, Brussels, Belgium., Goossens H; Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium., Malhotra-Kumar S; Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium., Tacconelli E; Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy., Vandamme T; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Peeters M; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., van Dam P; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Kumar-Singh S; Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.; Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2022 Dec 22; Vol. 13, pp. 1062136. Date of Electronic Publication: 2022 Dec 22 (Print Publication: 2022).
DOI:	10.3389/fimmu.2022.1062136
Abstrakt:	Background: Patients with cancer, especially hematological cancer, are at increased risk for breakthrough COVID-19 infection. So far, a predictive biomarker that can assess compromised vaccine-induced anti-SARS-CoV-2 immunity in cancer patients has not been proposed. Methods: We employed machine learning approaches to identify a biomarker signature based on blood cytokines, chemokines, and immune- and non-immune-related growth factors linked to vaccine immunogenicity in 199 cancer patients receiving the BNT162b2 vaccine. Results: C-reactive protein (general marker of inflammation), interleukin (IL)-15 (a pro-inflammatory cytokine), IL-18 (interferon-gamma inducing factor), and placental growth factor (an angiogenic cytokine) correctly classified patients with a diminished vaccine response assessed at day 49 with >80% accuracy. Amongst these, CRP showed the highest predictive value for poor response to vaccine administration. Importantly, this unique signature of vaccine response was present at different studied timepoints both before and after vaccination and was not majorly affected by different anti-cancer treatments. Conclusion: We propose a blood-based signature of cytokines and growth factors that can be employed in identifying cancer patients at persistent high risk of COVID-19 despite vaccination with BNT162b2. Our data also suggest that such a signature may reflect the inherent immunological constitution of some cancer patients who are refractive to immunotherapy. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Konnova, De Winter, Gupta, Verbruggen, Hotterbeekx, Berkell, Teuwen, Vanhoutte, Peeters, Raats, Massen, De Keersmaecker, Debie, Huizing, Pannus, Neven, Ariën, Martens, Bulcke, Roelant, Desombere, Anguille, Berneman, Goossens, Goossens, Malhotra-Kumar, Tacconelli, Vandamme, Peeters, van Dam and Kumar-Singh.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu